Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling(LMU Klinikum), Franck Morschhauser(Hôpital Claude Huriez), Krimo Bouabdallah(Université de Bordeaux), Dominique Bron(Institut Jules Bordet), David Cunningham(Royal Marsden Hospital), Sarit Assouline(Jewish General Hospital), G. Verhoef(KU Leuven), Kim Linton(The Christie NHS Foundation Trust), Catherine Thiéblemont(Sorbonne Paris Cité), Umberto Vitolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Florian Hiemeyer(Bayer (Germany)), Marius Giurescu(Bayer (Germany)), J. Garcia‐Vargas(Bayer (United States)), Igor Gorbatchevsky(Bayer (United States)), Li Liu(Bayer (United States)), Karl Koechert(Bayer (Germany)), Carol Peña(Bayer (United States)), Manoel Martins das Neves, B.H. Childs(Bayer (United States)), Pier Luigi Zinzani(Policlinico S.Orsola-Malpighi)
Cited by 271Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis